The company has launched Perampil, at 2 mg (Rs. 49/strip of 7 tablets), 4 mg (Rs. 180/strip of 15 tablets) and 6 mg (Rs. 300/strip of 15 tablets) to improve patient access
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
The new platform is the latest initiative under Lupin’s long running umbrella programme, Joint Airways Initiative (JAI), for patients suffering from respiratory ailment
Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)
These vaccine doses will be manufactured and stockpiled by the company from August-December 2021
Sun Pharma is granted rights for co-marketing of the drug in India in the private market under the brand name CARITEC
Aurobindo has one of the most enduring generics ecosystems among peers
Revenues from operations for FY21 stood at Rs. 202.38 crore as compared to 167.27 crore, up by 21%
India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
